GLTO

MKT CAP:$40M

Galecto, Inc.

Market Cap

$40M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$25.23+$3.41 (+15.63%)

Apr 23, 2026

Company Details

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatme...

CEO

Lori C. Firmani

IPO Date

Oct 29, 2020

Website

galecto.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$210M

EPS (Diluted)

-$4.57

Free Cash Flow

-$7M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Mar 19, 2026

$0EPS -$3.98

Q4 2025

Mar 19, 2026

$0EPS $2.31

Q3 2025

Nov 6, 2025

$0EPS -$2.36

Q2 2025

Aug 5, 2025

$0EPS -$2.60

Q1 2025

May 8, 2025

$0EPS -$1.92

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$17M
Q2 22	$0	$0	-$17M
Q3 22	$0	$0	-$14M
Q4 22	$0	$0	-$14M
Q1 23	$0	$0	-$13M
Q2 23	$0	$0	-$11M
Q3 23	$0	$0	-$9M
Q4 23	$0	$0	-$7M
Q1 24	$0	-$98.0K	-$6M
Q2 24	$0	$0	-$6M
Q3 24	$0	$0	-$4M
Q4 24	$0	-$5.0K	-$3M
Q1 25	$0	$0	-$3M
Q2 25	$0	$0	-$3M
Q3 25	$0	$0	-$3M
Q4 25	$0	-$7.0K	-$27M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$7M	-$7M
Q2 22	-$15M	-$15M
Q3 22	-$10M	-$10M
Q4 22	-$11M	-$11M
Q1 23	-$9M	-$9M
Q2 23	-$8M	-$8M
Q3 23	-$8M	-$8M
Q4 23	-$11M	-$11M
Q1 24	-$6M	-$6M
Q2 24	-$4M	-$4M
Q3 24	-$4M	-$4M
Q4 24	-$5M	-$5M
Q1 25	-$2M	-$2M
Q2 25	-$2M	-$2M
Q3 25	-$3M	-$3M
Q4 25	$566.0K	$566.0K

Capital Expenditures

Quarter	CapEx
Q1 22	$43.0K
Q2 22	$26.0K
Q3 22	$138.0K
Q4 22	$41.0K
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+25.0%
Q2 22	—	+39.6%
Q3 22	—	+5.3%
Q4 22	—	+0.4%
Q1 23	—	-20.3%
Q2 23	—	-34.8%
Q3 23	—	-37.0%
Q4 23	—	-50.7%
Q1 24	—	-57.4%
Q2 24	—	-50.0%
Q3 24	—	-55.3%
Q4 24	—	-59.4%
Q1 25	—	-54.7%
Q2 25	—	-38.7%
Q3 25	—	-17.8%
Q4 25	—	+911.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$1M	—
Q2 22	$1M	—
Q3 22	$1M	—
Q4 22	$1M	—
Q1 23	$1M	—
Q2 23	$1M	—
Q3 23	$1M	—
Q4 23	$1M	—
Q1 24	$1M	—
Q2 24	$891.0K	—
Q3 24	$681.0K	—
Q4 24	$308.0K	—
Q1 25	$179.0K	—
Q2 25	$172.0K	—
Q3 25	$164.0K	—
Q4 25	$483.0K	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$13M	$4M	—
Q2 22	$14M	$3M	—
Q3 22	$10M	$3M	—
Q4 22	$11M	$3M	—
Q1 23	$10M	$3M	—
Q2 23	$8M	$3M	—
Q3 23	$3M	$3M	—
Q4 23	$3M	$3M	—
Q1 24	$2M	$3M	—
Q2 24	$2M	$3M	—
Q3 24	$1M	$3M	—
Q4 24	$1M	—	$2M
Q1 25	$678.0K	$2M	—
Q2 25	$1M	$2M	—
Q3 25	$1M	$2M	—
Q4 25	$23M	—	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$45M	$48M	$94M
Q2 22	$30M	$49M	$79M
Q3 22	$28M	$41M	$69M
Q4 22	$33M	$27M	$60M
Q1 23	$25M	$28M	$53M
Q2 23	$23M	$29M	$52M
Q3 23	$23M	$21M	$44M
Q4 23	$21M	$12M	$33M
Q1 24	$21M	$6M	$27M
Q2 24	$23M	$0	$23M
Q3 24	$20M	$0	$20M
Q4 24	$14M	$0	$14M
Q1 25	$12M	$0	$12M
Q2 25	$10M	$0	$10M
Q3 25	$8M	$0	$8M
Q4 25	$258M	$0	$258M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	1M	0.0%	0.0%
Q2 22	1M	+0.0%	+0.0%
Q3 22	1M	+0.9%	+0.9%
Q4 22	1M	+0.6%	+1.5%
Q1 23	1M	+0.1%	+1.6%
Q2 23	1M	+2.7%	+4.4%
Q3 23	1M	+2.8%	+6.3%
Q4 23	1M	+0.0%	+5.8%
Q1 24	1M	-1.0%	+4.6%
Q2 24	1M	+1.0%	+2.8%
Q3 24	1M	+5.6%	+5.6%
Q4 24	1M	+1.1%	+6.7%
Q1 25	1M	+14.2%	+23.1%
Q2 25	1M	+0.0%	+21.9%
Q3 25	1M	+0.3%	+15.9%
Q4 25	2M	+20.4%	+38.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	40
Q2 22	$0	40
Q3 22	$0	40
Q4 22	$0	45
Q1 23	$0	45
Q2 23	$0	45
Q3 23	$0	45
Q4 23	$0	13
Q1 24	$0	13
Q2 24	$0	13
Q3 24	$0	13
Q4 24	$0	5
Q1 25	$0	5
Q2 25	$0	5
Q3 25	$0	5
Q4 25	$0	7

Revenue / Employee